Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,230.12
(
0.29%
)
US TECH 100
26,942.00
(
0.87%
)
Dow Jones
49,499.27
(
-0.31%
)
Brent Oil
107.80
(
0.00%
)
Bitcoin
78,978.89
(
0.38%
)
News Focus
News Focus
Post# of 447762
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

dukesking

Send PM Follow Ignore
Followers 26
Posts 3558
Boards Moderated 0
Alias Born 11/12/2018

dukesking

Re: couldbebetter post# 374943

Friday, 04/15/2022 3:26:24 PM

Friday, April 15, 2022 3:26:24 PM

Post# of 447762
CBB, It could be the recent formulary changes coupled with the recent Vascepa educational conferences/CE’s, and AMRN business strategies starting to pay off. Particularly formulary changes. It looks like we took shares from the generics and added some new scripts. For the reasons I stated, I expect the trend to continue gradually going forward. IMO.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent AMRN News
More AMRN News